New cholesterol drug VSA003 passes first safety test in healthy volunteers

NCT ID NCT05851066

Completed Disease control Sponsor: Visirna Therapeutics HK Limited Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-phase study tested a single dose of VSA003 in 36 healthy Chinese adults to see if it is safe and how the body handles it. The drug aims to help control high cholesterol and triglycerides. Participants received either VSA003 or a placebo, and researchers monitored for side effects and drug levels in the blood.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: VSA003
What this could lead to: If successful, this could lead to a new treatment option for managing high cholesterol and triglycerides.
What could go wrong: This is an early phase 1 trial in healthy volunteers, so it only tests safety and drug processing, not effectiveness. It may not work in patients or may have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DYSLIPIDEMIAS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Dyslipidemias familial hypercholesterolemia hyperlipidemia Hyperlipoproteinemia Type II hypertriglyceridemia inherited lipid metabolism disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DYSLIPIDEMIAS FAMILIAL HYPERCHOLESTEROLEMIA HYPERTRIGLYCERIDEMIA

Contacts and locations

Locations

Peking Union Medical College Hospital

Beijing, Beijing Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.